Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878969 · ClinicalTrials.gov registry record · Phase 3
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
A Phase 3 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT00878969 is a Phase 3 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 78 participants.
The verdict
NCT00878969, a Phase 3 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
The purpose of the study is to see how two classes of blood pressure medications,angiotensin-converting enzyme inhibitors (Ace inhibitors) and angiotensin receptor blockers (ARBs), differ in their long term effects on certain chemicals in the body and on the carotid arteries.
Interventions
- DRUG Placebo
- DRUG valsartan (ARB)
- DRUG ramipril (ACE inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878969
The ClinicalTrials.gov registry entry for NCT00878969 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00878969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878969 about?
NCT00878969 is a clinical study titled "Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3". The purpose of the study is to see how two classes of blood pressure medications,angiotensin-converting enzyme inhibitors (Ace inhibitors) and angiotensin receptor blockers (ARBs), differ in their long term effects on certain chemicals in the body and on the carotid arteries.
What is the current status of trial NCT00878969?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2010-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00878969?
The interventions under investigation include: Placebo (DRUG), valsartan (ARB) (DRUG), ramipril (ACE inhibitor) (DRUG).
Who is sponsoring clinical trial NCT00878969?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.